KR102688389B1 - 마크로시클릭 광범위 항생제 - Google Patents

마크로시클릭 광범위 항생제 Download PDF

Info

Publication number
KR102688389B1
KR102688389B1 KR1020227033626A KR20227033626A KR102688389B1 KR 102688389 B1 KR102688389 B1 KR 102688389B1 KR 1020227033626 A KR1020227033626 A KR 1020227033626A KR 20227033626 A KR20227033626 A KR 20227033626A KR 102688389 B1 KR102688389 B1 KR 102688389B1
Authority
KR
South Korea
Prior art keywords
compound
alkyl
pharmaceutically acceptable
amino
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227033626A
Other languages
English (en)
Korean (ko)
Other versions
KR102688389B9 (ko
KR20220137165A (ko
Inventor
마이클 프리드리히 토마스 코흘러
피터 앤드류 스미스
다나 윈터
부바카 소우
클라우디오 스투리노
길라움 펠레티어
조나단 보드롤트
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Priority to KR1020247021145A priority Critical patent/KR102764861B1/ko
Publication of KR20220137165A publication Critical patent/KR20220137165A/ko
Application granted granted Critical
Publication of KR102688389B1 publication Critical patent/KR102688389B1/ko
Publication of KR102688389B9 publication Critical patent/KR102688389B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020227033626A 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제 Active KR102688389B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247021145A KR102764861B1 (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962853457P 2019-05-28 2019-05-28
US62/853,457 2019-05-28
PCT/US2020/034670 WO2020243155A1 (en) 2019-05-28 2020-05-27 Macrocyclic broad spectrum antibiotics
KR1020217042492A KR102450071B1 (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217042492A Division KR102450071B1 (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247021145A Division KR102764861B1 (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제

Publications (3)

Publication Number Publication Date
KR20220137165A KR20220137165A (ko) 2022-10-11
KR102688389B1 true KR102688389B1 (ko) 2024-07-24
KR102688389B9 KR102688389B9 (ko) 2026-04-08

Family

ID=73551292

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227033626A Active KR102688389B1 (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제
KR1020257002841A Pending KR20250020719A (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제
KR1020247021145A Active KR102764861B1 (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제
KR1020217042492A Active KR102450071B1 (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020257002841A Pending KR20250020719A (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제
KR1020247021145A Active KR102764861B1 (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제
KR1020217042492A Active KR102450071B1 (ko) 2019-05-28 2020-05-27 마크로시클릭 광범위 항생제

Country Status (33)

Country Link
US (2) US11208387B2 (https=)
EP (2) EP4289480A3 (https=)
JP (3) JP7078807B2 (https=)
KR (4) KR102688389B1 (https=)
CN (2) CN114007605B (https=)
AR (1) AR119019A1 (https=)
AU (2) AU2020282975B2 (https=)
BR (1) BR112021024010A2 (https=)
CA (1) CA3141853A1 (https=)
CL (1) CL2021003153A1 (https=)
CO (1) CO2021017561A2 (https=)
CR (1) CR20210682A (https=)
DK (1) DK3968983T3 (https=)
ES (1) ES2961566T3 (https=)
FI (1) FI3968983T3 (https=)
HR (1) HRP20231497T8 (https=)
HU (1) HUE063847T2 (https=)
IL (2) IL295889B2 (https=)
LT (1) LT3968983T (https=)
MA (1) MA55981B1 (https=)
MX (1) MX2021014554A (https=)
NZ (1) NZ783605A (https=)
PE (2) PE20230383A1 (https=)
PH (1) PH12021552972A1 (https=)
PL (1) PL3968983T3 (https=)
PT (1) PT3968983T (https=)
RS (1) RS64852B1 (https=)
SA (1) SA521430976B1 (https=)
SG (1) SG11202112920SA (https=)
SI (1) SI3968983T1 (https=)
TW (1) TWI815017B (https=)
WO (1) WO2020243155A1 (https=)
ZA (1) ZA202502195B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072635B2 (en) 2015-11-20 2021-07-27 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
KR102602837B1 (ko) * 2021-03-08 2023-11-15 차의과학대학교 산학협력단 항독력활성을 가지는 화합물
CN113583003A (zh) * 2021-08-05 2021-11-02 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
CN113933416B (zh) * 2021-09-30 2023-10-10 海南海灵化学制药有限公司 一种注射用硫酸头孢匹罗中杂质的检测方法
CN120187860A (zh) 2022-11-11 2025-06-20 基因泰克公司 N-烷基氨基酸的酶促不对称合成
CN117946013B (zh) * 2024-01-25 2024-07-02 白银康寓信生物科技有限公司 一锅法合成5,6-二卤代-3-氨基吡嗪-2-甲酸甲酯的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018149419A1 (en) 2017-02-15 2018-08-23 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
JP2018135357A (ja) 2012-01-31 2018-08-30 ピエール、ファブレ、デルモ‐コスメティークＰｉｅｒｒｅ Ｆａｂｒｅ Ｄｅｒｍｏ−Ｃｏｓｍｅｔｉｑｕｅ 新規な光保護系
JP2018184435A (ja) 2012-11-21 2018-11-22 アールキューエックス ファーマシューティカルズ，インク． 大環状広域抗生物質

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128280A (en) 1959-10-23 1964-04-07 Searle & Co 1-(alkoxylated/halogenated phenyl)-3-pyridylmethylureas
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
EP0862638A1 (en) 1995-11-03 1998-09-09 E.I. Du Pont De Nemours And Company Positive selection vector for bacillus sp.
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
GB9902399D0 (en) 1999-02-03 1999-03-24 Smithkline Beecham Plc Compounds
US6660832B1 (en) 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
CN1839150A (zh) 2003-07-17 2006-09-27 麦根克斯有限公司 脂肽抗菌衍生物组合物及其应用方法
DE10358824A1 (de) 2003-12-16 2005-07-21 Bayer Healthcare Ag Antibakterielle Makrozyklen mit substituiertem Biphenyl
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
DE102005014247A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen VI
AU2011223790A1 (en) 2010-03-01 2012-08-30 Myrexis, Inc. Compounds and therapeutic uses thereof
CN102939095A (zh) 2010-03-09 2013-02-20 默沙东公司 增强β-内酰胺抗菌药物的活性的桥联脂糖肽类
WO2011120071A1 (en) 2010-04-01 2011-10-06 The University Of Queensland Oxytocin peptide analogues
BR112013006265A2 (pt) 2010-09-15 2016-06-07 Scripps Research Inst espectros antibióticos gerais análogos a arilomicina
TWI642684B (zh) 2011-05-27 2018-12-01 Ｒｑｘ製藥股份有限公司 廣效性抗生素
US10501493B2 (en) 2011-05-27 2019-12-10 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
CN103159830B (zh) 2011-12-15 2017-06-20 上海来益生物药物研究开发中心有限责任公司 脂肽类化合物
CA2867448A1 (en) * 2012-03-14 2013-09-19 Floyd E. Romesberg Broad spectrum antibiotic arylomycin analogs
CN103788176A (zh) 2012-10-31 2014-05-14 上海来益生物药物研究开发中心有限责任公司 一种arylomycin类化合物及其制备方法和应用
WO2015179441A2 (en) 2014-05-20 2015-11-26 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
ITUB20154591A1 (it) 2015-10-12 2017-04-12 Crestoptics S R L Apparato di microscopia confocale e relativo procedimento di acquisizione ed elaborazione di immagini
US11072635B2 (en) 2015-11-20 2021-07-27 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
TWI725075B (zh) 2015-11-20 2021-04-21 美商Ｒｑｘ製藥公司 巨環廣效抗生素
ES2892173T3 (es) 2017-03-27 2022-02-02 Hoffmann La Roche Procedimiento para fabricar análogos de anillo de arilomicina
CN111386283A (zh) 2017-09-29 2020-07-07 基因泰克公司 肽抗菌复合物及其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018135357A (ja) 2012-01-31 2018-08-30 ピエール、ファブレ、デルモ‐コスメティークＰｉｅｒｒｅ Ｆａｂｒｅ Ｄｅｒｍｏ−Ｃｏｓｍｅｔｉｑｕｅ 新規な光保護系
JP2018184435A (ja) 2012-11-21 2018-11-22 アールキューエックス ファーマシューティカルズ，インク． 大環状広域抗生物質
WO2018149419A1 (en) 2017-02-15 2018-08-23 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Brown et al., Bioorganic and Medicinal Chemistry Letters, 2014, Vol.24, p.413-418
Liu et al., J. Am. Chem. Soc., 2011, Vol.133, p.17869-17877

Also Published As

Publication number Publication date
AU2020282975A1 (en) 2022-01-20
CO2021017561A2 (es) 2022-01-17
SA521430976B1 (ar) 2023-12-11
JP2024147560A (ja) 2024-10-16
TWI815017B (zh) 2023-09-11
KR102688389B9 (ko) 2026-04-08
BR112021024010A2 (pt) 2022-05-17
FI3968983T3 (fi) 2023-11-01
AU2020282975B2 (en) 2023-02-02
TW202404953A (zh) 2024-02-01
CA3141853A1 (en) 2020-12-03
LT3968983T (lt) 2023-10-10
EP3968983A4 (en) 2022-06-22
CR20210682A (es) 2022-06-02
KR102450071B1 (ko) 2022-09-30
IL288294A (en) 2022-01-01
MX2021014554A (es) 2022-03-17
JP7508507B2 (ja) 2024-07-01
EP3968983B1 (en) 2023-09-13
PH12021552972A1 (en) 2022-07-25
NZ790559A (en) 2025-05-02
RS64852B1 (sr) 2023-12-29
AR119019A1 (es) 2021-11-17
CN114007605B (zh) 2022-07-15
TW202110812A (zh) 2021-03-16
NZ783605A (en) 2022-08-26
PT3968983T (pt) 2023-10-04
KR20250020719A (ko) 2025-02-11
HRP20231497T8 (hr) 2024-08-02
JP2022137011A (ja) 2022-09-21
PE20230383A1 (es) 2023-03-06
EP4289480A2 (en) 2023-12-13
HRP20231497T1 (hr) 2024-03-01
KR20240101729A (ko) 2024-07-02
JP7078807B2 (ja) 2022-05-31
JP7842812B2 (ja) 2026-04-08
MA55981B1 (fr) 2024-02-29
KR20220003629A (ko) 2022-01-10
CN115215923A (zh) 2022-10-21
KR20220137165A (ko) 2022-10-11
IL295889A (en) 2022-10-01
JP2022525693A (ja) 2022-05-18
MA55981A (fr) 2022-03-23
IL288294B (en) 2022-09-01
SI3968983T1 (sl) 2023-11-30
US11208387B2 (en) 2021-12-28
IL295889B1 (en) 2024-09-01
WO2020243155A1 (en) 2020-12-03
ZA202502195B (en) 2025-10-29
SG11202112920SA (en) 2021-12-30
CN114007605A (zh) 2022-02-01
HUE063847T2 (hu) 2024-02-28
CL2021003153A1 (es) 2022-07-29
KR102764861B1 (ko) 2025-02-06
ES2961566T3 (es) 2024-03-12
DK3968983T3 (da) 2023-10-30
EP4289480A3 (en) 2024-02-21
AU2023200369B2 (en) 2024-10-24
US20200377463A1 (en) 2020-12-03
US20220135528A1 (en) 2022-05-05
PE20240066A1 (es) 2024-01-11
PL3968983T3 (pl) 2024-03-18
IL295889B2 (en) 2025-01-01
EP3968983A1 (en) 2022-03-23
AU2023200369A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
KR102688389B1 (ko) 마크로시클릭 광범위 항생제
KR102764861B9 (ko) 마크로시클릭 광범위 항생제
KR102450071B9 (ko) 마크로시클릭 광범위 항생제
TWI631127B (zh) 巨環廣效抗生素
CN109219596B (zh) 大环广谱抗生素
CN108884058A (zh) 大环广谱抗生素
HK40076912A (en) Macrocyclic broad spectrum antibiotics
TWI919116B (zh) 大環廣效型抗生素
HK40060729B (en) Macrocyclic broad spectrum antibiotics
HK40060729A (en) Macrocyclic broad spectrum antibiotics
RU2834484C2 (ru) Макроциклические антибиотики широкого спектра действия
HK40002868A (en) Macrocyclic broad spectrum antibiotics
HK40000284B (zh) 大环广谱抗生素

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16 Ip right document amended

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16 A copy of ip right certificate issued

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16 Ip right document amended

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16 A copy of ip right certificate issued

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

R15 Change to inventor requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R15-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R15-X000 Change to inventor requested

St.27 status event code: A-5-5-R10-R15-oth-X000

P16 Ip right document amended

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16 A copy of ip right certificate issued

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

R16 Change to inventor recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R16-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R16-X000 Change to inventor recorded

St.27 status event code: A-5-5-R10-R16-oth-X000

P19 Errors in documents containing ipogçös decisions corrected

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P19-OTH-PG1701 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20260408

Republication note text: Request for Correction Notice

Gazette number: 1026883890000

Gazette reference publication date: 20240724